#USA #Boston #Mabtech #Sai Life Sciences #EYRA

Mabtech and Sai Life Sciences: A Strategic Alliance for Immunology

Mabtech, a renowned Swedish company specializing in life science tools, has recently announced a strategic collaboration with Sai Life Sciences, a leading global Contract Research Organization (CRO). The partnership aims to broaden the availability of Mabtech's cutting-edge EYRA™ multiplex immunology platform across the United States. This collaboration is particularly significant as it opens doors for advanced immunological capabilities tailored for biopharma and biotech sectors.

EYRA Platform Introduction

The EYRA platform represents a breakthrough in immunoassay technology, addressing constraints typically seen in traditional flow-based and plate-based systems. By enabling the detection of multiple analytes simultaneously with reduced hands-on time and complete automation readiness, EYRA offers a streamlined approach to immune profiling, catering to both routine and complex research demands. The system's success in leading academic institutions and biopharma companies across Europe and North America marks it as a significant advancement in immunological research.

In a recent statement, Kimberlee Parent, Head of U.S. Operations at Mabtech, emphasized the importance of accessibility to advanced immunology tools, stating, "This collaboration reflects Mabtech's commitment to making advanced immunology tools accessible to researchers wherever they work." The Boston location will act as a dedicated hub where Sai's scientists can leverage the EYRA platform for various applications including immuno-oncology and vaccine development.

Collaboration Details

Under this collaboration, Sai's Boston discovery laboratory will be designated as a co-marketing and execution hub. The experts from both companies will jointly deliver high-sensitivity multiplex immunology assay services, facilitate custom panel development, and conduct demonstrations of the EYRA platform.

Maneesh Pingle, Head of Discovery Services at Sai Life Sciences, shared insights on the significance of this partnership. “For our discovery clients, the ability to generate reliable, decision-enabling data early in a program is critical. By establishing our Boston site as a U.S. execution hub for EYRA-enabled immunology workflows, we are significantly strengthening Sai's capability to support complex programs in immunology and immuno-oncology.” This strategic move will allow for a seamless integration of immune profiling into broader research strategies, expediting the translation from biological hypotheses to confident clinical development decisions.

Business Development and Impact

In addition to the operational aspects, Mabtech and Sai Life Sciences will engage in joint business development efforts targeting U.S.-based biopharma and biotech firms. Focus areas for their initiatives include immuno-oncology, vaccine immunogenicity, and inflammation. The partnership will also feature a co-branded thought leadership program, which includes collaborative case studies, white papers, and presentations at significant immunology conferences, establishing a strong leadership status in the field.

The collaboration combines Mabtech's assay expertise with Sai's translational capabilities, creating a powerhouse for high-quality and reproducible immune profiling. As both companies join forces, they aim to set a new standard in immunology research and foster innovations that may lead to breakthroughs in therapeutic developments.

About Mabtech and Sai Life Sciences

Founded on a principle of scientific excellence, Mabtech is engaged in the development of monoclonal antibodies, immunoassay kits, and cutting-edge instrumentation. With a commitment to supporting advanced immunology research worldwide, its product portfolio includes ELISpot and FluoroSpot technologies alongside the EYRA platform. On the other hand, Sai Life Sciences is a global CRO known for its role in providing comprehensive research and manufacturing services. Tasks ranging from early drug discovery to clinical development characterize Sai's extensive partnerships with major biopharma companies, aimed at accelerating novel therapeutic developments.

As Mabtech and Sai Life Sciences embark on this new chapter, the landscape of immunology research in the U.S. is set to evolve significantly, paving the way for improved health outcomes supported by methodical and robust data-driven decisions.